CN105985347A - 一种苯并大环内酰胺吲哚生物碱及其在制备抗补体药物中的用途 - Google Patents
一种苯并大环内酰胺吲哚生物碱及其在制备抗补体药物中的用途 Download PDFInfo
- Publication number
- CN105985347A CN105985347A CN201510044966.XA CN201510044966A CN105985347A CN 105985347 A CN105985347 A CN 105985347A CN 201510044966 A CN201510044966 A CN 201510044966A CN 105985347 A CN105985347 A CN 105985347A
- Authority
- CN
- China
- Prior art keywords
- benzo
- complement
- indole
- indigo naturalis
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 230000002391 anti-complement effect Effects 0.000 title claims abstract description 9
- 108010008730 anticomplement Proteins 0.000 title claims abstract description 9
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 title abstract description 10
- 229930005303 indole alkaloid Natural products 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title abstract 2
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical class C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 230000037361 pathway Effects 0.000 claims abstract description 9
- 230000004154 complement system Effects 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 5
- 230000005764 inhibitory process Effects 0.000 claims abstract description 4
- XYQBKGGTARXXER-UHFFFAOYSA-N indol-3-ylidenemethanone Chemical group C1=CC=C2C(=C=O)C=NC2=C1 XYQBKGGTARXXER-UHFFFAOYSA-N 0.000 claims abstract description 3
- 230000000295 complement effect Effects 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003513 alkali Substances 0.000 claims description 14
- 125000005605 benzo group Chemical group 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 9
- 150000003951 lactams Chemical class 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 6
- -1 lactams indole alkaloid compounds Chemical class 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000004007 reversed phase HPLC Methods 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000007445 Chromatographic isolation Methods 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000002386 leaching Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 6
- 229940124073 Complement inhibitor Drugs 0.000 abstract description 3
- 239000004074 complement inhibitor Substances 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- ZTNBSFMIFOLVCM-UHFFFAOYSA-N 20S-Dimethylamino-3alpha-methoxypregn-5-ene Natural products C12CCC3(C)C(C(C)N(C)C)CCC3C2CC=C2C1(C)CCC(OC)C2 ZTNBSFMIFOLVCM-UHFFFAOYSA-N 0.000 abstract 2
- PZZXYDQKZIGACT-UHFFFAOYSA-N 5-hydroxyskytanthine Natural products C1N(C)CC(C)C2(O)C1C(C)CC2 PZZXYDQKZIGACT-UHFFFAOYSA-N 0.000 abstract 2
- 102100031315 AP-2 complex subunit mu Human genes 0.000 abstract 1
- 101000796047 Homo sapiens AP-2 complex subunit mu Proteins 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 206010018910 Haemolysis Diseases 0.000 description 20
- 230000008588 hemolysis Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 230000001629 suppression Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- 241000382362 Persicaria tinctoria Species 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000003171 anti-complementary effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000257673 Strobilanthes cusia Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属中药制药领域,涉及一种苯并大环内酰胺吲哚生物碱青黛碱C及其在制备抗补体药物中的用途。本发明从青黛粉末中分离得到一个结构新颖独特的苯并大环内酰胺吲哚生物碱青黛碱C,其由两个完全相同的3-羰基吲哚螺合在苯并内酰胺大环上;本发明采用现代药理实验证实其对补体系统经典途径和旁路途径激活均有较强的抑制作用,其CH50和AP50值分别为0.018±0.004mg/ml、0.042±0.014mg/ml。所述化合物可用于制备补体抑制剂。
Description
技术领域
本发明属中药制药领域,涉及青黛中一种苯并大环内酰胺吲哚生物碱及其在制备抗补体药物中的用途。
背景技术
研究公开了补体系统的过度激活会引发系统性红斑狼疮(SLE)、类风湿性关节炎(RA)、急性呼吸窘迫综合征(ARDS)等多种重大疾病。抗补体药物研究多年来一直是世界药学研究的热点和重点。然而目前对此类疾病尚缺乏较为理想的治疗药物,因此临床上急需高效、低毒、专一的新型补体抑制剂。从天然产物中研究开发补体抑制剂是近年来一个受到越来越多关注的重要研究领域,其具有成本低、毒性低等特点。国内外学者已从包括海洋生物在内的多种天然产物中分离得到多种具有补体系统抑制作用的单体化合物,为抗补体药物的研究与开发提供了广阔的前景。
青黛(Indigo Naturalis)为爵床科植物马蓝Baphicacanthus cusia(Nees)Bremek.、蓼科植物蓼蓝Polygonum tinctorium Ait.或十字花科植物菘蓝Isatisindigotica Fort.的叶或茎叶经加工制得的干燥粉末或团块。其性咸味寒,归肝经。可清热解毒、凉血消斑、泻火定惊。用于温毒发斑、血热吐衄、胸痛咳血、口疮、痄腮、喉痹、小儿惊痫。现代药理研究表明,青黛具有抗菌、抗炎、抗肿瘤、抗氧化、治疗银屑病等作用,其活性成分主要是生物碱类成分,以吲哚生物碱二聚体靛玉红、靛蓝等为主。
本发明拟提供一种苯并大环内酰胺吲哚生物碱的新化合物及其在制备抗补体药物中的用途。
发明内容
本发明的目的是提供一种苯并大环内酰胺吲哚生物碱青黛碱C及其在制备抗补体药物中的用途。
本发明提供的新结构化合物苯并大环内酰胺吲哚生物碱,命名为青黛碱C,由两个完全相同的3-羰基吲哚螺合在苯并内酰胺大环上,具有以下化学结构:
本发明应用现代药理筛选方法,对中药青黛中抗补体活性物质进行研究,从青黛的乙醇提取物分离得到一个苯并大环内酰胺吲哚生物碱类化合物青黛碱C,经活性测试,证实其对补体系统的经典途径和旁路途径激活均有较强的抑制作用。
本发明所述的化合物通过下述方法制备:
取青黛粉末,乙醇回流提取,合并提取液并浓缩得浸膏,加水混悬,分别以石油醚、乙酸乙酯和正丁醇萃取,合并萃取液并浓缩至干。将乙酸乙酯萃取部位经硅胶柱色谱分离、Sephadex LH-20柱色谱、反相HPLC等手段纯化,分离得到化合物青黛碱C。
所述化合物青黛碱C:黄色粉末,分子式C24H17N3O4,。ESI-MS m/z:434[M+Na]+。1H-NMR(400MHz,CDCl3)δH:7.59(1H,d,J=7.7Hz),7.46(1H,dd,J=8.3Hz,7.2Hz),7.44(1H,d,J=7.8Hz),7.26(1H,dd,J=8.3Hz,7.2Hz),7.14(1H,dd,
J=8.1Hz,7.1Hz),6.87(1H,d,J=8.2Hz),6.84(1H,d,J=8.2Hz),6.83(1H,dd,J=7.8Hz,7.2Hz),6.69(1H,d,J=8.1Hz),6.67(1H,dd,J=8.3Hz,7.2Hz),6.53(1H,d,J=8.3Hz),3.31(1H,d,J=16.4Hz),2.71(1H,d,J=16.4Hz).13C-NMR(100MHz,CDCl3)δC:70.3(C-2),202.9(C-3),118.6(C-3a),124.6(C-4),119.1(C-5),138.5(C-6),112.7(C-7),163.7(C-7a),36.3(C-8),172.8(C-9),128.8(C-11),154.6(C-12),116.1(C-13),130.1(C-14),119.4(C-15),120.5(C-16),83.6(C-2'),199.8(C-3'),118.2(C-3a'),123.9(C-4'),118.7(C-5'),138.2(C-6'),111.3(C-7'),162.0(C-7a').。
上述青黛碱C经过体外抗补体活性试验测定,结果表明其对补体系统的经典途径和旁路途径激活均有较强的补体抑制作用,其CH50和AP50值分别为其CH50和AP50值分别为0.018±0.004、0.042±0.014mg/ml。阳性对照肝素CH50和AP50值分别为0.026±0.005mg/ml、0.054±0.016mg/ml。
所述的苯并大环内酰胺吲哚生物碱类化合物青黛碱C可用于制备抗补体药物。
附图说明
图1是青黛中青黛碱C的提取分离流程图。
具体实施方式
实施例1制备青黛碱C
取青黛粉末5kg,95%乙醇回流提取3次(50L×3),每次2h,合并提取液并浓缩得浸膏0.25kg,加水(4L)混悬,分别以等体积石油醚、乙酸乙酯和正丁醇萃取5次,合并萃取液并浓缩至干,得乙酸乙酯萃取物50g。将乙酸乙酯萃取部位经硅胶(200-300目)柱色谱分离,依次以二氯甲烷-甲醇(50:1-0:1)梯度洗脱,得到8个流份(Fr.1-8),其中流份Fr.5(4g)再经硅胶柱色谱(二氯甲烷-甲醇,30:1,20:1,10:1,5:1,3:1,1:1)、Sephadex LH-20柱色谱(氯仿-甲醇,1:1)和反相HPLC(甲醇-水,20:80-80:20梯度洗脱)等手段纯化,分离得到化合物青黛碱C。
所述化合物青黛碱C:黄色粉末,分子式C24H17N3O4,。ESI-MS m/z:434[M+Na]+。1H-NMR(400MHz,CDCl3)δH:7.59(1H,d,J=7.7Hz),7.46(1H,dd,J=8.3Hz,7.2Hz),7.44(1H,d,J=7.8Hz),7.26(1H,dd,J=8.3Hz,7.2Hz),7.14(1H,dd,J=8.1Hz,7.1Hz),6.87(1H,d,J=8.2Hz),6.84(1H,d,J=8.2Hz),6.83(1H,dd,J=7.8Hz,7.2Hz),6.69(1H,d,J=8.1Hz),6.67(1H,dd,J=8.3Hz,7.2Hz),6.53(1H,d,J=8.3Hz),3.31(1H,d,J=16.4Hz),2.71(1H,d,J=16.4Hz).13C-NMR(100MHz,CDCl3)δC:70.3(C-2),202.9(C-3),118.6(C-3a),124.6(C-4),119.1(C-5),138.5(C-6),112.7(C-7),163.7(C-7a),36.3(C-8),172.8(C-9),128.8(C-11),154.6(C-12),116.1(C-13),130.1(C-14),119.4(C-15),120.5(C-16),83.6(C-2'),199.8(C-3'),118.2(C-3a'),123.9(C-4'),118.7(C-5'),138.2(C-6'),111.3(C-7'),162.0(C-7a').。
实施例2体外抗补体经典途径试验
取补体(豚鼠血清)0.04ml,加入巴比妥缓冲液(BBS)配制成1:10的溶液,用BBS对倍稀释成1:20、1:40、1:80、1:160、1:320、1:640和1:1280的溶液,取1:1000溶血素、2%羊红细胞(SRBC)各0.1ml及各浓度补体0.2ml溶于0.2ml BBS中,混匀,37℃水浴30min后放入低温高速离心机,在4000rpm、4℃条件下离心5min。分别取每管上清0.2ml于96孔板,在405nm测定其吸光度。实验同时设置全溶血组(0.1ml 2%SRBC、0.1ml溶血素溶于0.4ml三蒸水)。以三蒸水溶血管的吸光度作为全溶血标准,计算溶血率。以补体稀释度为X轴,溶血百分率为Y轴作图。选择达到相似高溶血率的最低补体浓度作为确保体系能正常溶血所需的临界补体浓度。取临界浓度的补体与供试品混匀,按上述方法于405nm下测定吸光度。实验同时设置供试品对照组、补体组和全溶血组。将供试品吸光度值扣除相应供试品对照组吸光度值后计算溶血率。以供试品浓度作为X轴,溶血抑制率作为Y轴作图,计算50%抑制溶血所需供试品的浓度(CH50),结果为0.018±0.004mg/ml;阳性对照肝素CH50值为0.026±0.005mg/ml。
实施例3体外抗补体旁路途径试验
取补体(人血清)0.2ml,加入AP稀释液(巴比妥缓冲液,pH=7.4,含5mMMg2+,8mM EGTA)配制成1:5的溶液,并对倍稀释成1:10、1:20、1:40、1:80、1:160、1:320和1:640的溶液。取各浓度补体0.15ml、AP稀释液0.15ml及0.5%兔红细胞(RE)0.20ml,混匀,37℃水浴30min后置于低温高速离心机,在4000rpm、4℃条件下离心5min。分别取每管上清0.2ml于96孔板,在405nm测定吸光度。实验同时设置全溶血组(0.20ml 0.5%RE溶于0.3ml三蒸水)。以三蒸水溶血管的吸光度作为全溶血标准,计算溶血率。以补体稀释度为X轴,溶血百分率为Y轴作图。选择达到相似高溶血率的最低补体浓度作为确保体系能正常溶血所需的临界补体浓度。取确定的临界浓度的补体与供试品混匀,按上述方法于405nm下测定其吸光度。实验同时设置供试品对照组、补体组和全溶血组。将供试品吸光度值扣除相应供试品对照组吸光度值后计算溶血率。以供试品浓度作为X轴,溶血抑制率作为Y轴作图,计算50%抑制溶血所需供试品的浓度(AP50),结果为0.042±0.014mg/ml;阳性对照肝素AP50值为0.054±0.016mg/ml。
本发明中,实验采用的试剂均为本领域公知技术,可市购。
Claims (5)
1.具有如下化学结构的苯并大环内酰胺吲哚生物碱类化合物,
所述化合物命名为青黛碱C,由两个完全相同的3-羰基吲哚螺合在苯并内酰胺大环上。
2.按权利要求1所述的苯并大环内酰胺吲哚生物碱类化合物,其特征在于,通过下述方法制备:
取中药青黛粉末,95%乙醇回流提取3次,每次2h,合并提取液并浓缩得浸膏,加水混悬,分别以等体积石油醚、乙酸乙酯和正丁醇萃取5次,合并萃取液并浓缩至干,得乙酸乙酯萃取物;将乙酸乙酯萃取部位经硅胶,200-300目,柱色谱分离,依次以二氯甲烷-甲醇,50:1-0:1,梯度洗脱,得到8个流份,Fr.1-8,其中流份Fr.5再经硅胶柱色谱其中,二氯甲烷-甲醇,30:1,20:1,10:1,5:1,3:1,1:1、Sephadex LH-20柱色谱其中,氯仿-甲醇,1:1和反相HPLC其中甲醇-水,20:80-80:20梯度洗脱,纯化,分离得到化合物青黛碱C。
3.权利要求1所述的苯并大环内酰胺吲哚生物碱类化合物在制备抗补体药物中的用途。
4.按权利要求3所述的用途,其特征在于,所述的苯并大环内酰胺吲哚生物碱类化合物对补体系统的经典途径有补体抑制作用。
5.按权利要求3所述的用途,其特征在于,所述的苯并大环内酰胺吲哚生物碱类化合物对补体系统的旁路途径激活有补体抑制作用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510044966.XA CN105985347B (zh) | 2015-01-29 | 2015-01-29 | 一种苯并大环内酰胺吲哚生物碱及其在制备抗补体药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510044966.XA CN105985347B (zh) | 2015-01-29 | 2015-01-29 | 一种苯并大环内酰胺吲哚生物碱及其在制备抗补体药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105985347A true CN105985347A (zh) | 2016-10-05 |
CN105985347B CN105985347B (zh) | 2017-12-01 |
Family
ID=57034257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510044966.XA Expired - Fee Related CN105985347B (zh) | 2015-01-29 | 2015-01-29 | 一种苯并大环内酰胺吲哚生物碱及其在制备抗补体药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105985347B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110267672A (zh) * | 2016-12-20 | 2019-09-20 | 首尔大学医院 | 用于预防或治疗炎性肠病的包含青黛提取物或其级分作为有效成分的药物组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103087020A (zh) * | 2011-10-31 | 2013-05-08 | 复旦大学 | 紫草酚类化合物及其在制备抗补体药物中的用途 |
CN103508919A (zh) * | 2012-06-25 | 2014-01-15 | 复旦大学 | 生物碱类化合物及其在制备抗补体药物中的用途 |
-
2015
- 2015-01-29 CN CN201510044966.XA patent/CN105985347B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103087020A (zh) * | 2011-10-31 | 2013-05-08 | 复旦大学 | 紫草酚类化合物及其在制备抗补体药物中的用途 |
CN103508919A (zh) * | 2012-06-25 | 2014-01-15 | 复旦大学 | 生物碱类化合物及其在制备抗补体药物中的用途 |
Non-Patent Citations (3)
Title |
---|
M. SALVINI等: "Alpha-tryptophan synthase of Isatis tinctoria:gene cloning and expression", 《PLANT PHYSIOLOGY AND BIOCHEMISTRY》 * |
姚志昂等: "三十八批青黛的对比研究", 《成都中医药大学学报》 * |
徐晗等: "天然产物中的抗补体活性成分", 《中国天然药物》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110267672A (zh) * | 2016-12-20 | 2019-09-20 | 首尔大学医院 | 用于预防或治疗炎性肠病的包含青黛提取物或其级分作为有效成分的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN105985347B (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101242850A (zh) | 文冠果的提取物和从提取物分离出的化合物的组成,功能和应用,以及它们的制备方法 | |
CN102643322B (zh) | 一种同时制备长梗冬青苷和紫丁香苷的方法 | |
CN103508919B (zh) | 生物碱类化合物及其在制备抗补体药物中的用途 | |
CN113321618B (zh) | 马齿苋中三种生物碱类化合物及其提取分离方法 | |
CN101890084A (zh) | 黑种草子总苷提取物及其制备方法和应用 | |
CN105985347A (zh) | 一种苯并大环内酰胺吲哚生物碱及其在制备抗补体药物中的用途 | |
CN107028964A (zh) | 山柰酚‑7‑O‑α‑L‑鼠李糖苷在制备预防和治疗新陈代谢综合征药物方面的应用 | |
CN114249784B (zh) | 一种香豆素衍生物化合物ⅲ、提取方法及其用途 | |
CN105982899A (zh) | 青黛酮在制备抗补体药物中的用途 | |
CN104231019B (zh) | 单萜苷类化合物在制备抗补体药物中的用途 | |
CN101766664A (zh) | 一种岗梅总皂苷的提取方法及其质量检测方法 | |
CN105985403B (zh) | 一种甾醇内酯及其在制备抗补体药物中的用途 | |
CN110156784B (zh) | 一种吲哚型生物碱11-mt及其制备方法和应用 | |
CN105985341A (zh) | 卡巴唑型吲哚生物碱及其在制备抗补体药物中的用途 | |
CN105520926A (zh) | 木脂素类化合物(7s,8r)-二氢脱氢二松柏醇在制备抗补体药物中的用途 | |
CN105777683A (zh) | 双环醇的药物组合物及其医药用途 | |
CN103083342B (zh) | 黄烷类化合物在制备抗补体药物中的用途 | |
CN105985402A (zh) | 一种甾醇内酰胺化合物马勃内酰胺及其在制备抗补体药物中的用途 | |
CN106606506A (zh) | 对映半日花烷型二萜在制备抗补体药物中的用途 | |
CN105777686A (zh) | 酒石酸麦角胺的药物组合物及其在生物医药中的应用 | |
CN106589043B (zh) | 芳基取代丙烯酰基三萜类化合物在制备抗补体药物中的用途 | |
CN108017683B (zh) | 一种多聚羟基孕甾烷化合物及其制备方法和在制备抗补体药物中的用途 | |
CN114249776B (zh) | 一种香豆素衍生物化合物ⅱ、提取方法及其用途 | |
CN113307817B (zh) | 马齿苋中一种吡咯类生物碱化合物及其提取分离方法 | |
CN106038573A (zh) | 一种柠檬苦素类化合物在制备治疗肾癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171201 |
|
CF01 | Termination of patent right due to non-payment of annual fee |